Gene Editing Market Research 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides
DUBLIN--(BUSINESS WIRE)--Jun 3, 2025--
The 'Gene Editing Markets 2025-2029 by Application, Technology, Place, Industry and Product with Executive & Consultant Guides' report has been added to ResearchAndMarkets.com's offering.
This comprehensive view of the gene editing landscape highlights the technology's potential to drive transformative change. As breakthroughs become more frequent, businesses need to stay informed about the latest trends and projections. Those equipped with thorough market insights are poised to leverage these technologies effectively, ensuring competitive advantages in their respective fields.
Gene Editing is moving from strength to strength. CRISPR and similar tools are finding new uses in every area of biotechnology. It started with Medical applications by changing genes in living human cells. Uncurable diseases have already being cured. More are on the way.
The market for gene editing tools is witnessing a surge, with rapid growth driven by technological advances. These tools are broadening their reach beyond healthcare, offering groundbreaking possibilities in agriculture, biofuel production, and more. Major players in the biotechnology industry are spearheading research to develop innovative applications, ensuring continual market evolution.
Industry experts indicate that the gene editing industry is set to continue its rapid expansion. Companies and researchers are actively investigating diverse opportunities in areas such as crop improvement, pest control, and sustainable resource management. These developments position gene editing as a cornerstone technology, promising significant impacts on global food security and sustainable practices.
The gene editing market is becoming increasingly sophisticated, with new applications and technologies emerging regularly. As demand for more precise and efficient biotechnological solutions grows, the sector continues to attract substantial investment. Key players are focusing on research and development, strengthening their market positions, and pushing forward innovations to meet both current needs and future challenges.
Key Topics Covered:
1 Market Guides
1.1 Strategic Situation Analysis
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
2 Introduction and Market Definition
2.1 Methodology
2.1.1 Methodology
2.1.2 Sources
2.1.3 Authors
2.2 What is Gene Editing?
2.3 The CRISPR Example
2.3.1 What is CRISPR?
2.3.2 The CRISPR Family
2.4 Chromosomes, Genes and Epigenetics
2.4.1 Chromosomes
2.4.2 Genes
2.4.3 Epigenetics
2.5 Market Definition
2.5.1 Revenue Market Size
2.6 Perspective: Healthcare Spending
2.6.1 Global Healthcare Spending
2.6.2 Spending on Healthcare and Pharmaceuticals
2.6.3 Spending on Diagnostics
2.6.4 Important Role of Insurance for Medical Services
3 Market Structure
3.1 Market Structure Therapeutics
3.1.1 Research and Development (R&D) Companies
3.1.2 Biotechnology Companies
3.1.3 Generic Drug Manufacturers
3.1.4 Big Pharmaceuticals
3.1.5 Contract Research Organizations (CROs)
3.1.6 Contract Manufacturing Organizations (CMOs)
3.1.7 Specialty Pharmaceutical Companies
3.1.8 Pharmaceutical Distributors
3.1.9 Retail Pharmacies
3.1.10 Wholesalers
3.1.11 Online Pharmacies
3.1.12 Health Technology Companies
3.1.13 Pharmacy Benefit Managers (PBMs)
3.1.14 Clinical Laboratories
3.1.15 Medical Device Companies
3.1.16 Regulatory Bodies
3.2 Market Structure Diagnostics
3.2.1 Academic Research Lab
3.2.2 Diagnostic Test Developer
3.2.3 Instrumentation Supplier
3.2.4 Chemical/Reagent Supplier
3.2.5 Pathology Supplier
3.2.6 Independent Clinical Laboratory
3.2.7 Public National/regional Laboratory
3.2.8 Hospital Laboratory
3.2.9 Physicians Office Lab (POLS)
3.2.10 Audit Body
3.2.11 Certification Body
4 Market Trends
4.1 Factors Driving Growth
4.1.1 Cell Therapy
4.1.2 Gene Therapy
4.1.3 The New Agriculture
4.1.4 Genetics and Cell Metabolism
4.2 Factors Limiting Growth
4.2.1 The Cost Curve
4.2.2 Time and Trials
4.2.3 The Price Barrier
5 Recent Developments in Gene Editing
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 CRISPR tool allows for remote-controlled gene-editing
5.3 CRISPR Making Sweeter Tomatoes
5.4 Researchers Create gene-edited prawns
5.5 Gene Editing Corrects Cystic Fibrosis
5.6 CRISPR gene editing to change healthcare?
5.7 CrisprBits Collaborates With MolBio Diagnostics
5.8 Sherlock Bioscience to Launch Free AI-Based Operating System
5.9 Sherlock Biosciences to Acquire Sense Biodetection
5.10 CRISPR Enzyme Discovery Opens New Applications
5.11 Sherlock Biosciences Adds Ambient Amplification to Toolkit
5.12 Rice University Adapts CRISPR Enzyme
5.13 Princeton Group Develops Cas13 Assay for Point-of-Care Use
5.14 Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC System
5.15 Sherlock Biosciences Raises $80M
5.16 Broad Institute Considers CRISPR Respiratory Panels to Replace PCR
5.17 Medix Biochemica Acquires MyPols Biotec
5.18 Mammoth Biosciences High-Throughput CRISPR-Based COVID Test Gets EUA
5.19 Genome Diagnostics Makes €1M Investment in Scope Biosciences
5.20 CRISPR Test Could be used for Asymptomatic Screening
5.21 Mammoth Biosciences, Agilent to Comarket CRISPR-Based SARS-CoV-2 Test
5.22 Pandemic Accelerates Development of CRISPR Diagnostics
5.23 ERS Genomics Licenses CRISPR Patents to Vivlion
5.24 Mammoth Bio Signs Commercialization Deal for SARS CoV-2 Test
5.25 ERS Genomics, FASMAC to Commercialize CRISPR-Cas9
5.26 The Nobel Prize in Chemistry 2020 - CRISPR Wins
6 Key Companies
6.1 10x Genomics, Inc.
6.2 4D Molecular Therapeutics
6.3 Abeona Therapeutics
6.4 Acrigen Biosciences
6.5 Adarx Pharmaceuticals
6.6 Adverum Biotechnologies
6.7 Affini-T Therapeutics
6.8 Agilent
6.9 Arbor Biotechnologies
6.10 Arcturus Therapeutics
6.11 Axxam
6.12 Beam Therapeutics
6.13 Beckman Coulter Diagnostics (Danaher)
6.14 Becton, Dickinson and Company
6.15 Binx Health
6.16 bioMerieux Diagnostics
6.17 Bio-Rad Laboratories, Inc.
6.18 Bluebird Bio
6.19 Caribou Biosciences
6.20 Cell Microsystems
6.21 Cellenion (BICO)
6.22 Century Therapeutics
6.23 Chroma Medicine
6.24 Creative Biogene
6.25 Crispr Therapeutics
6.26 Editas Medicine
6.27 ERS Genomics
6.28 FASMAC
6.29 Genscript Biotech
6.30 Illumina
6.31 Inscripta
6.32 Intellia Therapeutics
6.33 J&J Innovative Medicine
6.34 Locus Biosciences
6.35 Mammoth Biosciences
6.36 Metagenomi
6.37 Myllia Biotechnology
6.38 Namocell
6.39 NRGene
6.40 Poseida Therapeutics
6.41 Precision Biosciences
6.42 Prime Medicine
6.43 Proof Diagnostics
6.44 Regeneron Pharmaceuticals
6.45 Revvity
6.46 Roche Diagnostics
6.47 Sherlock Biosciences
6.48 Thermo Fisher Scientific
6.49 Twist Bioscience
6.50 Verve Therapeutics
6.51 Vivlion
6.52 Wave Life Science
7 The Global Market for Gene Editing
7.1 Global Market Overview by Country
7.2 Global Market by Application - Overview
7.3 Global Market Technology - Overview
7.4 Global Market Type - Overview
7.5 Global Market Industry - Overview
7.6 Global Market Product - Overview
8 Gene Editing Markets - By Application
8.1 Cell Line
8.2 Plant
8.3 Animal
8.4 Cell Therapy
8.5 Gene Therapy
8.6 Diagnostics
8.7 Research
9 Global Gene Editing Markets - by Technology
9.1 Crispr
9.2 Talens
9.3 ZFN
9.4 Meganuclease
10 Gene Editing Markets - by Place
10.1 In Vivo
10.2 Ex Vivo
10.3 In Vitro
11 Gene Editing Markets - by Industry
11.1 Pharma
11.2 Clinical
11.3 Academic
11.4 Contract
12 Global Gene Editing Markets - by Product
12.1 Instruments
12.2 Cells
12.3 Reagents
13 Appendices
13.1 United States Medicare System: laboratory Fees Schedule
13.2 The Most Used IVD Assays
13.3 The Highest Grossing Assays
13.4 The Whole Genome Sequence of SARS-CoV-2
13.5 Global Listing of Sequencing Establishments - Location & Contacts
For more information about this report visit https://www.researchandmarkets.com/r/hjfds4
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250603426444/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: HEALTH GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2025.
PUB: 06/03/2025 09:49 AM/DISC: 06/03/2025 09:47 AM
http://www.businesswire.com/news/home/20250603426444/en
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 minutes ago
- Business Wire
Impart Security Raises $12M Series A for Production-Trusted AI Security Platform
SAN FRANCISCO--(BUSINESS WIRE)--Impart Security today announced the general availability of the industry's first Application Detection and Response Engineering Platform, which security teams trust to build autonomous workflows for production environments. The launch comes alongside a $12 million Series A funding round led by Madrona Ventures, with participation from CRV and 8-Bit Capital. As a result of the financing, Madrona Managing Director Karan Mehandru has joined the board. Impart's breakthrough platform already protects major enterprises, including a major financial services firm and a global entertainment conglomerate, by defending against threats in real-time without requiring human oversight, achieving what security experts called impossible until now. "This isn't just about better security tools—we're fundamentally changing how enterprises engineer application protection," said Jonathan DiVincenzo, CEO of Impart Security. "When AI can be trusted to manage production changes without oversight, it transforms from an assistant into an autonomous operator. That's the difference between traditional approaches to application security and genuine business transformation." The Fundamental Problem – Enterprise security teams have long been trapped in an impossible tradeoff: allowing attacks through or risking production outages. Traditional security solutions force teams to choose between robust protection and system stability, leading most organizations to operate with minimal security settings rather than risk disrupting critical business operations. This defensive posture leaves applications vulnerable to the very threats security teams are tasked to prevent. The Breakthrough: Programmable WASM Rules – While fully autonomous application security has been promised for years, trust and safety concerns have prevented real-world deployment. Impart's platform leverages WebAssembly isolation technology to create secure sandbox environments where security teams, assisted by AI agents, can design, develop, and test security rules against live traffic patterns without risk of lateral movement or production impact. Not only does WASM provide secure isolation, but it's also highly performant with ahead-of-time compilation and portable across platforms. This foundational innovation unlocks unparalleled safety and agility in Impart's platform, allowing security teams to rapidly iterate and deploy security controls in production environments with unprecedented speed and confidence. Early results demonstrate the impact: Impart's AI has successfully deployed over 2,400 security rules across customer environments, reducing average deployment time from 18 days to 45 minutes while maintaining 99.97% uptime—better than most human-managed security systems. "We've evaluated every AI native security platform on the market, but they all had the same fatal flaw: they still required human review for production changes," said Chris Castaldo, CISO at Crossbeam. "Impart is the first platform our team trusts to make autonomous production changes. In three months, it's caught dozens of attack patterns our previous tools missed entirely while never causing a single service disruption." Autonomous Security Engineering at Scale – Impart's platform deploys a growing number of specialized AI agents that function as a coordinated team of application security engineers, including: Traffic Inspector – Continuously inspects traffic flows to identify behavioral patterns and baselines Detection Engineer – Spots anomalies and potential threats as they emerge in real-time Security Architect – Develops and tests security rules within isolated sandbox environments Rule Engineer – Adapts defenses based on new attack vectors and threat intelligence The technology recently proved its value during a sophisticated application attack targeting multiple Impart customers simultaneously. While traditional security teams would have required days to analyze the attack pattern and deploy a virtual patch, Impart's AI identified the threat signature, generated custom detection rules, and deployed protection across all affected environments within minutes of the initial attack. Investor Validation After Rigorous Technical Diligence – "We evaluated dozens of AI security companies, but Impart was the only one that stood out because of its breadth, depth, and usability," said Karan Mehandru, Managing Director at Madrona. "Every enterprise we speak with desperately wants to leverage the incredible benefits of AI and unlock innovation, yet none of that is possible without a comprehensive security platform that is proactive, fully autonomous, AI-native, and ultimately removes the burden from security teams who are drowning in point tools. The feedback we received from multiple CISOs we spoke with was unambiguous and overwhelmingly positive about Impart's differentiation as a product and their leadership team, led by Jonathan DiVincenzo. It is clear to us that Impart has solved the last mile problem that had previously limited AI from being truly transformative in enterprise and from deploying applications into production." Industry Transformation Ahead – The Series A funding will accelerate Impart's expansion into three key enterprise segments: financial services, healthcare, and infrastructure providers—industries where security speed directly impacts business operations. The company is also launching partnerships with major cloud platforms and channel partners to integrate autonomous security capabilities directly into enterprise deployment pipelines. "We're thrilled to partner with Karan and the team at Madrona," said DiVincenzo. "As we enter our next phase of growth, Karan's go-to-market expertise will be invaluable as we expand our sales and marketing efforts while continuing to strengthen the platform that has resonated so strongly with the market." About Impart Security Impart Security delivers the world's first AI security platform trusted to operate autonomously in production environments. Using code based rules and an integrated security IDE, Impart provides adaptive, intelligent protection for APIs and web applications without human oversight or operational burden. Founded by security veterans from major technology companies, Impart is backed by Madrona and serves Fortune 500 enterprises across financial services, healthcare, and cloud infrastructure. Learn more at
Business Wire
21 minutes ago
- Business Wire
Snaile Appoints Two Industry Veterans to Drive Strategic Growth and Market Expansion
TORONTO--(BUSINESS WIRE)--Snaile is pleased to announce the appointment of Nicholas (Nick) Thadaney, ICD.D, and Vikram Kapoor, CFA, to its Strategic Advisory Board—marking a pivotal step in the company's next phase of growth. Nick Thadaney, former CEO of the Toronto Stock Exchange (TSX) and Group Head of Capital Formation at TMX, brings unmatched expertise in capital markets, technology, corporate governance, and innovation leadership. His guidance will be instrumental as Snaile refines its commercial activities as well as scaling its operations and reinforcing its position as a leader in smart parcel infrastructure. Vikram Kapoor is a seasoned capital markets strategist and portfolio manager with deep experience in investment management, corporate finance, and value creation. He has advised and led numerous high-impact transactions across sectors involving some of Canada's largest exits, and his insights will support Snaile's continued expansion nationally and into international markets. With their strategic counsel and guidance, Snaile is poised to redefine last-mile logistics through the expansion of its secure, carrier-agnostic smart locker platform—a scalable solution for e-commerce, retail, and pharmaceutical distribution. These appointments mark a transformative chapter for Snaile. We are not only advancing smart locker technology—we are building the infrastructure to power the future of digital commerce. Stay tuned for more updates as we continue to unlock new opportunities and deliver innovative solutions to meet the evolving demands of the modern marketplace.
Business Wire
26 minutes ago
- Business Wire
Madison Global Becomes 100% Employee-Owned
NEW YORK--(BUSINESS WIRE)--Madison Global, a premier provider of social recognition solutions and group meetings and events, proudly announces its transition to a 100% employee-owned company through the successful completion of its Employee Stock Ownership Plan (ESOP). This milestone marks Madison as one of the first in its sector to achieve full employee ownership, reinforcing its commitment to people-first values and long-term sustainability. For 50 years, Madison has empowered organizations to inspire, engage, and recognize their employees, said Alex Alaminos, President & CEO of Madison Global. Today, we're proud to extend that same spirit of recognition inward by becoming 100% employee-owned. 'For over 50 years, Madison has empowered organizations to inspire, engage, and recognize their employees,' said Alex Alaminos, President & CEO of Madison Global. 'Today, we're proud to extend that same spirit of recognition inward. Becoming 100% employee-owned is more than a structural change—it's a bold affirmation of our belief that our people are our greatest asset. It aligns our collective success directly with those who drive it every day.' An ESOP is a qualified retirement plan that provides employees with beneficial ownership of the company through shares held in a trust. With this transition, all shares of Madison Global are now held by its employees, ensuring that every team member has a direct stake in the company's future. The advantages of employee ownership extend far beyond structure, delivering strategic value that includes: Stronger employee engagement and morale: A shared sense of ownership encourages deeper commitment and accountability. Reduced turnover: Employee-owned companies typically experience greater retention and loyalty. Operational resilience: ESOP companies often demonstrate stronger performance through economic cycles. Financial advantages: ESOPs bring tax efficiencies that enhance cash flow and support reinvestment. Talent attraction and retention: Ownership can be a compelling differentiator in competitive job markets. Madison's ESOP journey began in 2023 as part of a long-term succession and growth strategy focused on preserving independence while amplifying its legacy of innovation and service excellence. 'Since founding Madison in 1974, I've always believed that great companies are built by great people,' said Werner Haase, Founder and Executive Chairman. 'This transition ensures that our team—who have always been the heart of our success—are now also the stewards of our future. It's a proud moment and a natural evolution of our values.' As Madison Global enters this new chapter, it remains focused on delivering exceptional client experiences—now powered by the passion, purpose, and partnership of 100% employee ownership. About ESOPs The Employee Stock Ownership Plan (ESOP) is a retirement benefit that enables employees to earn shares of stock in the company where they work. First created in 1974, there are approximately 6,700 ESOP businesses in the United States, employing about 14 million employee-owners. At Madison Global, the ESOP benefit is being provided in addition to other benefits. According to research compiled by the National Center for Employee Ownership (NCEO), ESOP-owned companies tend to outperform comparable firms in their industry and show more resilience in recessions. Employees in firms with an ESOP have 2.2 times as much in retirement savings compared to employees in non-ESOP companies. About Madison As a global leader in Social Recognition and Groups, Meetings & Events, Madison provides enterprise-class organizations with employee recognition, incentives and service anniversary programs designed for the needs of today's ever-changing workforce. Madison's recognition strategy focuses on making managers mentors, reinforcing a sense of belonging, celebrating personal and professional milestones, and emphasizing inclusion and diversity.
